BioWorld - Saturday, November 23, 2024

U.S.
U.S. RSS Feed RSS

DNA data illustration
J.P. Morgan Healthcare Conference

Population genetic studies set up for success, as they aim for health care and research results

Jan. 15, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – Major genetic research efforts designed to encompass millions of people globally have been setting up their infrastructure in recent years to serve both researchers and patients. This work is being done by major national initiatives, such as All of Us in the U.S. and Genomics England in the U.K., as well as by health care systems such as Intermountain and Kaiser.
Read More
Cancer cell and DNA
J.P. Morgan Healthcare Conference

Guardant embraces biopharma research, screening to maintain momentum

Jan. 15, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – Guardant Health Inc. has set the standard for liquid biopsy. That success has catapulted the Redwood City, Calif.-based company from an IPO in the fall of 2018 to a current valuation in excess of $7 billion. It has made its name – and much of its revenue – with its Guardant360 test, a molecular diagnostic test that assesses 74 cancer-related genes from the circulating tumor DNA to aid in designing the best treatment for advanced cancer patients with solid tumors.
Read More
Gavel and scales

Supreme Court passes on Athena patent case despite Solicitor General’s endorsement

Jan. 14, 2020
By Mark McCarty
No Comments
The U.S. Supreme Court has declined to hear the case of Athena v. Mayo, which many hoped would ease the patent subject matter eligibility problem. This outcome leaves Congress and the Court of Appeals for the Federal Circuit as the only likely sources of resolution for the problem, but there is skepticism as to whether either of these parties is both willing and able to overcome the impasse.
Read More
Business pipeline illustration
J.P. Morgan Healthcare Conference

Medtronic spotlights pipeline, as Ishrak cedes stage a bit to incoming CEO Martha

Jan. 13, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – This was the final presentation for Omar Ishrak at the J.P. Morgan (JPM) Healthcare Conference. He has held the CEO position at Medtronic plc since June 2011. During that period, the Dublin-based company managed to roughly quadruple its valuation to $160 billion from $40 billion – making Ishrak’s tenure clearly a successful one.
Read More
1-13-dexcom-G6-Transmitter-Sensor.png
J.P. Morgan Healthcare Conference

Dexcom dips despite upbeat focus on moving into the masses with T2, pregnancy, hospital

Jan. 13, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – Dexcom Inc. is working hard to take its business to the next level. Wall Street has been rewarding it heavily, doubling its market cap to about $21 billion since the end of 2018. But investors pulled back a tad on the company’s presentation at the J.P. Morgan (JPM) Healthcare Conference in San Francisco, sending shares down about 4% despite beating analyst expectations.
Read More
Tau protein in Alzheimer's disease

Tau PET imaging offers the potential to predict the progress of Alzheimer’s disease

Jan. 7, 2020
By Stacy Lawrence
No Comments
Amyloid and tau proteins are both involved in the disease pathology of Alzheimer’s disease. The diagnostic and treatment research focus has long been on amyloid, which has proven almost entirely fruitless after decades of effort. But tau is becoming better understood, as investigational tau imaging agents offer the ability to visualize its presence in the brain.
Read More

Attorneys say final rules for Stark, AKS drafts unlikely to emerge this year

Jan. 6, 2020
By Mark McCarty
No Comments
The draft rules for the Stark and Anti-Kickback statutes (AKS) seem to have excluded makers of devices, but Meena Datta of Sidley Austin told BioWorld MedTech that while these agencies have plenty of reasons to rethink that notion, the final rules are unlikely to emerge in 2020 simply because of the complexity of the undertaking. While the final rules may reverse the drafts’ exclusion of makers of devices and diagnostics, device makers were upbeat at the prospect that they could engage in value-based payment arrangements with providers.
Read More